Pemazyre (pemigatinib) — Medica
Myeloid/lymphoid neoplasms with eosinophilia and FGFR1 rearrangement
Initial criteria
- age ≥ 18 years
- eosinophilia present
- cancer has fibroblast growth factor receptor 1 (FGFR1) rearrangement detected by an approved test
Approval duration
1 year